Stay updated with breaking news from Primary Relief. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.
The company’s device, Primary Relief, is the latest of DyAnsys’ long list of devices to receive FDA clearance.
/PRNewswire/ -- DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following...
The FDA has cleared Primary Relief, a percutaneous electrical neurostimulation device, for symptomatic relief of postoperative pain following C-section delivery.
/PRNewswire/ -- DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been clearedto treat pain following a...